Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has also submitted a Supplemental NDA for DEXTENZA to include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication. Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix is currently evaluating each of OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Also, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) is in pre-clinical development as an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix's first product, ReSure® Sealant is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

Company profile
Ticker
OCUL
Exchange
Website
CEO
Antony Mattessich
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
I-THERAPEUTIX INC
SEC CIK
Corporate docs
Subsidiaries
Ocular Therapeutix Europe B.V. • Ocular Therapeutix Securities Corp. ...
OCUL stock data
News

Ocular Therapeutix's Return On Capital Employed Overview
6 Jun 22
Stocks That Hit 52-Week Lows On Friday
27 May 22
Stocks That Hit 52-Week Lows On Thursday
26 May 22
Expert Ratings for Ocular Therapeutix
10 May 22
JMP Securities Maintains Market Outperform on Ocular Therapeutix, Lowers Price Target to $20
10 May 22
Press releases
Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer
9 Jun 22
Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases
8 Jun 22
Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference
1 Jun 22
AffaMed Therapeutics Holds DEXTENZA Launch and Advisory Board Meeting in Macau
9 May 22
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
9 May 22
Analyst ratings and price targets
Current price
Average target
$15.33
Low target
$10.00
High target
$20.00
JMP Securities
Maintains
$20.00
HC Wainwright & Co.
Maintains
$10.00
Piper Sandler
Maintains
$16.00
Investment data
Securities sold
Number of investors
Calendar
9 May 22
26 Jun 22
31 Dec 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 147.18M | 147.18M | 147.18M | 147.18M | 147.18M | 147.18M |
Cash burn (monthly) | 6.25M | 5.33M | 5.94M | 6.3M | 6.2M | 5.57M |
Cash used (since last report) | 17.93M | 15.29M | 17.06M | 18.09M | 17.79M | 15.97M |
Cash remaining | 129.25M | 131.89M | 130.12M | 129.09M | 129.39M | 131.21M |
Runway (months of cash) | 20.7 | 24.7 | 21.9 | 20.5 | 20.9 | 23.6 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Jun 22 | Hong Seung Suh | Common Stock | Grant | Acquire A | No | No | 0 | 8,933 | 0 | 8,933 |
16 Jun 22 | Hong Seung Suh | Stock Option Common Stock | Grant | Acquire A | No | No | 3.43 | 26,800 | 91.92K | 26,800 |
16 Jun 22 | Heier Jeffrey S. | Common Stock | Grant | Acquire A | No | No | 0 | 8,933 | 0 | 47,933 |
16 Jun 22 | Heier Jeffrey S. | Stock Option Common Stock | Grant | Acquire A | No | No | 3.43 | 26,800 | 91.92K | 26,800 |
16 Jun 22 | Lindstrom Richard L MD | Common Stock | Grant | Acquire A | No | No | 0 | 8,933 | 0 | 108,402 |
16 Jun 22 | Lindstrom Richard L MD | Stock Option Common Stock | Grant | Acquire A | No | No | 3.43 | 26,800 | 91.92K | 26,800 |
16 Jun 22 | Warden Charles M | Common Stock | Grant | Acquire A | No | No | 0 | 8,933 | 0 | 48,464 |
16 Jun 22 | Warden Charles M | Stock Option Common Stock | Grant | Acquire A | No | No | 3.43 | 26,800 | 91.92K | 26,800 |
16 Jun 22 | Williams Leslie J. | Common Stock | Grant | Acquire A | No | No | 0 | 8,933 | 0 | 13,433 |
16 Jun 22 | Williams Leslie J. | Stock Option Common Stock | Grant | Acquire A | No | No | 3.43 | 26,800 | 91.92K | 26,800 |
Institutional ownership, Q1 2022
56.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 128 |
Opened positions | 14 |
Closed positions | 25 |
Increased positions | 44 |
Reduced positions | 42 |
13F shares | Current |
---|---|
Total value | 240.84M |
Total shares | 43.64M |
Total puts | 167.4K |
Total calls | 153.4K |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
Opaleye Management | 5.97M | $29.58M |
Summer Road | 5.94M | $29.43M |
BLK Blackrock | 5.07M | $25.09M |
Vanguard | 4.2M | $20.77M |
Deltec Asset Management | 2.08M | $10.28M |
STT State Street | 1.7M | $8.44M |
Citadel Advisors | 1.69M | $8.38M |
Geode Capital Management | 1.36M | $6.75M |
Emerald Advisers | 1.29M | $6.4M |
Emerald Mutual Fund Advisers Trust | 1.09M | $5.41M |
Financial report summary
?Competition
EyePoint Pharmaceuticals • Aerie Pharmaceuticals • Aldeyra Therapeutics • Ocugen • Kodiak Sciences • Kala Pharmaceuticals • Apellis Pharmaceuticals • Adverum Biotechnologies • Sight Sciences • Graybug VisionManagement Discussion
- We are a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using our proprietary bioresorbable hydrogel-based formulation technology. Core to our strategy is (i) to continue to build upon our experience commercializing ophthalmology products that can be administered primarily in the surgical and/or office settings and (ii) to continue to develop a clinical pipeline of innovative ophthalmology products that address large areas of unmet need.
- We currently have two FDA-approved products in commercialization in the United States: DEXTENZA, an intracanalicular insert for the treatment of both post-surgical ocular inflammation and pain and ocular itching associated with allergic conjunctivitis, and ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. We also have product candidates in preclinical and clinical development designed to utilize our proprietary, bioresorbable hydrogel technology to treat retinal diseases including wet age-related macular degeneration, or wet AMD; glaucoma and ocular hypertension; and ocular surface diseases and conditions including dry eye disease.
- We incorporate therapeutic agents that have previously received regulatory approval from the U.S. Food and Drug Administration, or FDA, including small molecules and proteins, into our proprietary bioresorbable hydrogel-based formulation technology in our internal drug development activities, with the goal of providing local programmed release to tailor the duration and amount of drug to be delivered to the eye. We believe that our local programmed-release drug delivery technology has the potential to treat conditions and diseases of both the front and the back of the eye and can be administered through a range of different modalities including intravitreal implants, suprachoroidal implants, intracameral implants and intracanalicular inserts.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
belonging, bulbar, bundled, cautioned, compelling, comprised, Cutler, Dorr, Exudation, Hale, highlighted, hyperemia, inflation, invoiced, ITT, optometric, photographic, Pickering, preserving, ratio, rolled, RSU, signal, sister, sponsorship, subcontractor, Super, titled, unmet, unsatisfied, Wilmer, WilmerHale
Removed:
abandon, abroad, abuse, abusive, ACA, academic, accelerated, accept, accident, Accountability, accruing, accuracy, accurate, achievement, acquired, acquirer, acquisition, acted, acuity, add, added, adding, Additionally, addressed, adequacy, adequately, adhere, adjusted, administrator, adult, advancement, advantage, adversarial, advisory, advocating, affirmative, affirmatively, affirmed, affordability, Affordable, afforded, aflibercept, Agency, aggressive, agree, agreeing, ahead, Aid, aim, alleging, alter, altogether, amend, amending, American, analytical, announcement, annually, Antony, appeal, appealed, applied, apply, applying, appointing, approach, approve, arbitration, Area, argument, arising, arm, arrange, arranging, art, ARVO, ASC, ascertain, Asia, asserted, asserting, assertion, assessing, assign, assigned, assigning, assignment, assistance, assuming, assure, attain, attempted, attending, attention, attestation, attract, attrition, augment, authorization, authorize, authorizing, automatic, avoiding, aware, bandage, bar, Bedford, begin, begun, Benchmark, beneficial, bidding, Biden, biodegradable, biologic, biometric, blurred, board, body, border, branded, breached, breadth, Brexit, bribery, bring, broad, broadly, brought, Budget, built, bulk, California, called, Canada, capable, capitalize, carefully, carried, carry, cast, catastrophic, categorized, CCPA, CE, cease, ceased, ceasing, certainty, certificate, cGMP, chain, challenge, challenged, challenging, charged, charter, chemical, children, Circuit, civil, claim, claimed, claiming, clear, clearance, cleared, closed, CMS, code, coded, coherence, collaborate, collaborative, collaborator, collateralized, collect, collected, collection, combining, commence, commenced, comment, commerce, commercialized, commissioned, commit, Committee, commonly, communicate, community, comparative, compare, comparing, comparison, compete, competent, competing, competitor, complementary, complex, compliant, complicating, complied, comply, complying, composition, compromise, compromised, computer, concealing, concentrated, concession, conclude, conclusive, Conference, confidence, confidential, confidentiality, confirm, confirmation, confirmed, conflict, conform, congressional, consent, considerable, consistently, constrain, construe, consult, consumer, contamination, contemplate, contested, continuation, continuously, contracting, contradictory, controlled, controlling, convenient, Cooperation, correct, corrective, correspondingly, Corrupt, corruption, Cosmetic, costly, counsel, counter, country, court, covenant, coverage, covered, covering, CPT, create, created, credible, criminal, CRL, Crosby, cultural, cumulative, curtail, curtailment, damage, damaged, dated, debarment, decide, decided, decision, declared, decline, declined, declining, decreased, decreasing, decree, dedicate, deductibility, deduction, deem, deemed, deemphasize, defect, defend, defendant, defended, defense, defer, deferral, defraud, delayed, demand, demonstrate, denied, Department, departure, depressing, depth, DER, derivation, design, designing, desirable, desire, destroyed, destruction, detailed, detect, detention, deter, determination, deterrent, deviation, devise, devote, devoted, DEXYCU, diabetic, diagnosed, diagnostic, difficulty, digit, diligence, dilute, dilution, dilutive, diminish, diminished, directing, disadvantage, disclose, discounting, discourage, discovered, discovering, discovery, discrete, discretion, disgorgement, dismissed, disposal, dispose, disproportionate, disrupt, disrupted, dissemination, dissuade, distract, distracting, distraction, distribute, distributed, distributing, district, diversify, diversion, divert, DME, documentation, documented, documenting, DOJ, domain, Dr, draft, drop, duct, durability, ease, economically, edema, EEA, effected, effectively, efficient, eIND, electrical, eligibility, eliminated, elimination, eluting, emerging, employed, employer, employment, enact, enacted, enactment, encounter, encourage, encumbering, enforce, enforceability, enforced, enforcement, English, enhance, enhanced, enlarge, enrolling, ensuring, environmental, error, escalating, ESPP, essential, essentially, establishment, ethical, EU, Europe, European, eventual, evolve, evolving, examination, exceed, exclude, exclusion, exclusively, exclusivity, execute, executing, execution, exempt, exemption, exercised, exhibited, exist, existence, exit, expensive, expertise, expired, exploratory, explore, exploring, export, expose, expressed, extending, extreme, extremely, eylea, face, facilitate, fact, factor, factual, fail, failed, failing, failure, fairly, fall, fallen, false, FASB, fashion, faster, favor, favored, FCA, FCPA, FDCA, fearful, feasibility, feature, federal, fee, fewer, FFCR, filer, finalized, Finally, firm, flare, flat, flexibility, float, floor, flow, fluctuate, forego, foreign, formal, formula, formulating, forthcoming, forward, found, framework, fraud, fraudulent, freely, frequency, frustrate, fulfilled, functioning, funded, furlough, furnish, gaining, gap, gathered, GDPR, generic, genetic, globally, glycol, govern, governance, governed, governing, governmental, graph, greater, group, guarantee, half, halt, hand, handling, harmed, harmful, head, headcount, healthcare, hear, hedging, heightened, higher, hinder, HIPAA, hire, hiring, historically, hold, holding, hostile, hypopyon, Icon, IDE, identical, identifiable, Identity, illegally, impair, impaired, impede, implement, implemented, implementing, import, importance, importation, impose, imposed, imposition, imprisonment, improper, improperly, inability, inadequate, inappropriate, Incept, incidence, incident, inconclusive, inconvenient, incorporation, incorrectly, increasing, increasingly, incremental, indefinitely, indemnify, independent, independently, individually, induce, inducement, inexpensively, inflammatory, influenced, influencing, informational, informed, infringe, infringed, infringement, infringing, inherently, inhibit, initiating, initiative, injunction, injury, inserting, inseverable, inside, inspected, inspection, inspectional, institute, instituted, institutional, insufficient, Integra, integrity, intense, intensity, intensive, intentional, inter, interference, interpretation, interpreted, interrupt, interrupted, introduction, invalid, invalidate, invalidated, invalidation, invalidity, invent, invention, inventor, inventorship, invested, investigating, investigation, investigational, investigator, invite, involving, irritation, issuable, issue, jeopardize, Jonathan, judge, judicial, jurisdiction, Justice, justify, kind, Kingdom, knowingly, labeled, labeling, laboratory, lack, lag, largely, larger, largest, launching, lawfully, led, legislation, legislative, lengthy, lessen, letter, liable, LIBOR, licensee, lieu, likelihood, likewise, link, liquefied, list, listing, literature, locate, located, location, lodge, long, lose, lost, lt, maintained, managed, managerial, mandate, mandatory, manner, manufacturer, marginal, marketable, marketed, marketer, marketplace, Mattessich, mature, McCarter, measuring, mechanism, media, Medicaid, medical, medically, Medicare, medication, medicinal, meet, member, merging, merit, mg, MidCap, minimal, minimum, misappropriated, misappropriation, misconduct, mitigation, moderately, modest, modestly, modification, modify, modulate, monetary, monitoring, morale, motivate, movement, narrow, narrowed, narrowly, nasolacrimal, nation, nationwide, natural, negatively, negotiate, negotiated, newly, NOL, nominal, noncompliance, nonrenewal, Northern, noteworthy, notification, notified, NSR, numerically, obligating, occlusion, occur, OCT, offered, official, offshore, onsite, operation, opposition, optical, Oral, Orange, originally, outline, outpatient, output, oversee, oversight, PA, packaging, paragraph, parallel, partial, partnering, PAS, passing, patentability, patentable, patenting, paying, PEG, pending, people, percentage, perception, permanent, permanently, permit, permitting, person, personal, perspective, pertaining, pertinent, pharmacoeconomic, pharmacovigilance, physical, pill, placebo, play, pocket, poison, policy, political, polyethylene, pool, Portability, portion, pose, post, postpone, potent, practical, practice, pre, preclude, predetermined, predictive, preempted, preissuance, prejudice, premarket, prematurely, premium, prepaid, preponderance, prescribe, prescribed, prescribing, prescription, presence, presenting, President, presidential, prevail, prevalence, prevalent, prevented, preventing, pricing, prioritization, prioritize, prioritizing, priority, privacy, problem, proceed, proceeding, processing, produce, produced, profit, profitable, profitably, progression, prohibit, prohibited, prolong, prolonged, promise, Promotional, promptly, promulgated, pronounced, properly, prophylactic, propose, proposed, prosecute, prosecuted, prosecution, prostaglandin, protected, protecting, protocol, protracted, proven, provision, provoke, proximal, proximity, PTAB, publication, publicity, publicly, published, purity, pursuit, put, qualified, qualifying, question, qui, quickly, radioactive, raw, reach, reaching, reaction, recall, recognizing, recommendation, recommending, reconsider, reconsideration, recording, recordkeeping, recoup, recover, recovery, recruit, recruiting, recurrence, redesign, reexamination, referral, reform, refrigerated, refusal, refuse, Regeneron, regime, register, registered, registration, registry, regulate, reimburse, reinstated, rejected, rejection, relate, relaxation, relaxing, relevant, reliability, reliably, relied, relief, relieve, relieved, relocate, relocated, relocation, reluctance, rely, remain, remanded, remediate, remove, removed, remuneration, render, renew, repatriated, repay, repeal, repealed, repeat, repeated, replace, replacing, replicated, reposition, representing, reprioritize, reproduce, reputation, reputational, request, requested, researching, Reserve, reserved, resolution, resolved, resource, respond, responded, responsibility, responsible, restitution, restoration, restrict, restructured, restructuring, retained, retaining, retroactively, retrospective, reviewing, revised, revocation, reward, robust, role, ruled, rulemaking, ruling, RVO, safe, safeguarding, safely, safer, satisfaction, satisfactorily, schedule, scheduled, scheme, Schirmer, scientific, scrutiny, secret, secured, securing, seeking, seizure, Senate, sensitive, sequester, served, servicing, serving, shareholder, sharing, shift, shipping, shorten, shortened, shortly, showing, shut, shutdown, side, Similarly, SISPQ, site, size, slight, slowdown, slower, softened, soliciting, sought, specifically, spectral, spend, spending, spiked, spread, ST, stability, stated, statute, statutory, stemming, step, sterilization, steroid, stinging, stop, storage, stored, Street, strength, strict, strong, stronger, structural, structure, submission, submitted, subsequent, substance, substantive, succeed, suffer, sufficiently, suggest, suit, suitable, Sunshine, supervisory, supplement, supplier, Supreme, surveillance, susceptible, suspend, suspension, sustain, sustained, system, tam, tasked, taxable, taxation, Taxpayer, teaching, tear, tearing, technical, teen, telecommunication, teleconference, temperature, temporarily, tentative, terrorism, test, therapy, threat, threshold, timeframe, tip, tolerability, tomography, top, tort, toxic, toxicity, tracking, Trademark, tradename, traditional, train, training, transition, transitional, transitioning, transmission, transparency, transport, traveling, treating, treble, trend, tribunal, trillion, Trump, twelve, type, ultimate, ultimately, unacceptable, unanticipated, unauthorized, unavailable, unclear, unconstitutional, undergoing, undermine, undesirable, unenforceable, unexpected, unfavorable, unforeseen, unintended, Union, unknown, unlocked, unmanaged, unnecessarily, unpatentability, unpatented, unpredictable, unrelated, unsatisfactory, unsuccessful, untitled, unused, unwilling, upgrade, USPTO, vaccination, validate, validated, validating, validity, vary, varying, vascular, VEGF, vein, venue, verified, version, viewed, violate, violated, violation, Virtual, virtually, visibility, vision, visit, visualize, visualized, volatile, volatility, voluntary, vulnerable, waiting, waive, Wall, war, warning, waste, whichever, whistleblower, wide, widely, widespread, willfully, withdrawal, withdrawn, withdrew, Wong, worker, working, worldwide, written
Financial reports
Current reports
8-K
Departure of Directors or Certain Officers
17 Jun 22
8-K
Departure of Directors or Certain Officers
8 Jun 22
8-K
Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update
9 May 22
8-K
Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update
28 Feb 22
8-K
Departure of Directors or Certain Officers
7 Feb 22
8-K
Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update
8 Nov 21
8-K
Departure of Directors or Certain Officers
22 Sep 21
8-K
Entry into a Material Definitive Agreement
9 Aug 21
8-K
Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update
9 Aug 21
8-K
Ocular Therapeutix™ Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million
22 Jul 21
Registration and prospectus
POS AM
Prospectus update (post-effective amendment)
28 Feb 22
S-8
Registration of securities for employees
28 Feb 22
POSASR
Automatic shelf registration (post-effective amendment)
28 Feb 22
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 21
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Aug 21
Proxies
DEFA14A
Additional proxy soliciting materials
2 May 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
PRE 14A
Preliminary proxy
13 Apr 21
DEFA14A
Additional proxy soliciting materials
15 Jun 20
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEFA14A
Additional proxy soliciting materials
25 Apr 19
DEF 14A
Definitive proxy
25 Apr 19
Other
EFFECT
Notice of effectiveness
11 May 22
CT ORDER
Confidential treatment order
24 Oct 19
EFFECT
Notice of effectiveness
30 Apr 19
CORRESP
Correspondence with SEC
24 Apr 19
UPLOAD
Letter from SEC
7 Apr 19
EFFECT
Notice of effectiveness
11 Feb 19
CORRESP
Correspondence with SEC
7 Feb 19
UPLOAD
Letter from SEC
7 Feb 19
CT ORDER
Confidential treatment order
19 Oct 18
CT ORDER
Confidential treatment order
17 Nov 16
Ownership
4
OCULAR THERAPEUTIX / MERILEE RAINES ownership change
21 Jun 22
4
OCULAR THERAPEUTIX / Leslie J. Williams ownership change
21 Jun 22
4
OCULAR THERAPEUTIX / Charles M Warden ownership change
21 Jun 22
4
OCULAR THERAPEUTIX / RICHARD L MD LINDSTROM ownership change
21 Jun 22
4
OCULAR THERAPEUTIX / Seung Suh Hong ownership change
21 Jun 22
4
OCULAR THERAPEUTIX / Jeffrey S. Heier ownership change
21 Jun 22
4
OCULAR THERAPEUTIX / RICHARD L MD LINDSTROM ownership change
16 May 22
4
OCULAR THERAPEUTIX / Jeffrey S. Heier ownership change
15 May 22
4
Change in insider ownership
23 Feb 22
SC 13G
OCULAR THERAPEUTIX / VANGUARD ownership change
10 Feb 22
Patents
Utility
Ocular Insert Containing a Glucocorticoid
16 Jun 22
In certain embodiments, the invention relates to a sustained release biodegradable intracanalicular insert containing a glucocorticoid dispersed in a hydrogel for the treatment of dry eye disease.
Utility
Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine
17 May 22
Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
Utility
Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine
5 Apr 22
Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
Utility
Sustained Release Biodegradable Intracanalicular Inserts Comprising a Hydrogel and Cyclosporine
24 Mar 22
Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
Utility
Sustained Release Biodegradable Intracanalicular Inserts Comprising a Hydrogel and Cyclosporine
24 Mar 22
Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.
Transcripts
2022 Q1
Earnings call transcript
10 May 22
2021 Q4
Earnings call transcript
1 Mar 22
2021 Q3
Earnings call transcript
9 Nov 21
2021 Q2
Earnings call transcript
10 Aug 21
2021 Q1
Earnings call transcript
6 May 21
2020 Q4
Earnings call transcript
12 Mar 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
7 Aug 20
2020 Q1
Earnings call transcript
8 May 20
2019 Q4
Earnings call transcript
12 Mar 20
Reddit threads
Daily Discussion Thread - May 9th, 2022
9 May 22
Daily Discussion Thread - May 6th, 2022
6 May 22
Daily Discussion Thread - February 28th, 2022
28 Feb 22
Daily Discussion Thread - February 25th, 2022
25 Feb 22
Thoughts on biotech
23 Jan 22
What are your top 5 value plays for 2022?
7 Jan 22
Daily Discussion Thread - November 8th, 2021
8 Nov 21
Daily Discussion Thread - November 5th, 2021
5 Nov 21
Penny Stocks w/ Potential Biotech Catalysts This Week - $ABUS $ADTX $ADVM + 6 more
10 Oct 21
Biotech Penny Stocks To Watch This Week With 'Stuff' Happening - $ABUS $KLDO $MNKD $ADVM $TRVN
3 Oct 21